Abstract 1600P
Background
Sarcopenia is a disorder that causes muscle mass and strength loss, which can result in diminished mobility and functional limits. Depression and a bad assessment of one's own health are common results among cancer patients. As a result, this study aimed to look at the association between sarcopenia, depression, and health perception.
Methods
Cancer patients were the subject of a retrospective study from January to April 2023. The study included 150 patients who had different forms of a verified cancer diagnosis. These individuals were admitted to Mayo Hospital's Palliative Care Cancer Department. The presence of depressive symptoms was assessed using the Patient Health Questionnaire (PHQ-9). SARC-F was used to measure all the five dimensions of sarcopenia. To examine self-perceived health, a self-report questionnaire was used. The relationships between sarcopenia, depression, and health perception were investigated using correlation analysis.
Results
We observed a significant and positive association between depression and the dimensions of sarcopenia. Specifically, we found a positive correlation between depression and SARC1=Strength (r = 0.378, p<0.01), SARC2=Assistance in walking (r = 0.390, p<0.01), SARC3=Rise from a chair (r = 0.488, p<0.01), and SARC4=Climb stairs (r = 0.392, p<0.01). However, we found a positive but insignificant relationship between depression and SARC5=Falls (r = 0.150, p>0.05). In addition, we discovered that patients' perception of poor health was correlated with depression (r = -0.391, p<0.01), SARC2=Assistance in walking (r = -0.235, p<0.01), SARC3=Rise from a chair (r = -0.259, p<0.01), and SARC4=Climb stairs (r = -0.277, p<0.01). However, we did not find a significant relationship between health perception and two dimensions of sarcopenia (i.e., SARC1=Strength and SARC5=Falls).
Conclusions
Sarcopenia adversely affects the physical and mental health of cancer patients. They feel depressed and perceive their health as bad which imparts a negative impact on the outcome of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05